About the Council
Priorities
Publications
Events

About the Council

 

The Healthcare Council works to highlight the potential of new biotechnology solutions, the pipeline of their applications and defines the implications these new tools will have on the European regulatory and legislative framework.

New advances in biological sciences combined with the acceleration of technological applications are transforming how healthcare is delivered to patients.

The Healthcare Council develops proposals in areas across the healthcare biotechnology landscape including: advanced therapy medicinal products (ATMPs), medicines for rare diseases and children (OMPs), regulatory efficiencies, market access and procurement.

The Council delivers the Patient BioForum as the platform of exchange of views between patient organisations and healthcare biotechnology members. The Council also delivers the Healthcare BioForum as a platform for exchange across the larger biotechnology and business ecosystem.

The Council meets three times per year to issue strategic advice and overall vision. It is supported by Working Groups across priority topics.

Healthcare Biotechnology in Action

Vision for Europe
  • OM Pharma
  • Cytiva
  • Disc Medicine
  • SwiftPharma
  • The Union of Biotechnological Companies BioForum
  • Freget Glaser & Associes
  • Olon Group
  • ASSOBIOTEC
  • Finnish BioIndustries
  • Alexion AstraZeneca Rare Disease
 

Priorities

 

The Healthcare Biotechnology Council has priorities selected by Members for shared work throughout the year, delivered through working groups and Council meetings.

Our priorities encompass the most pressing issues of our members within EU policy that concerns healthcare biotechnology.

 

Biopharmaceutical Strategy Group

The working group is tasked with advocacy delivery on behalf of the Healthcare Council on immediate legislative priorities to ensure the specific needs of healthcare biotechnology are duly considered by European policymakers.

OMP-ATMP Group

The working group is tasked with developing policies and narratives relevant for orphan medicines and advanced therapies to ensure patients can fully access and benefit from novel biotechnology treatments and therapeutics in the EU. 

 

Regulatory Affairs Group

The working group is tasked with developing policies and recommendation to enable a progressive regulatory framework for efficient uptake of new healthcare biotechnologies in the EU. The group actively engages with European regulators, including the European Medicines Agency.

Access & Value Group

The expert group is tasked with developing policies and recommendations relevant to market access and EU resilience, including on shortages, procurement, and supply-chains.